Francine Foss

Francine Foss was a principal investigator of the BELIEF trial that led to FDA approval of belinostat for relapsed/refractory PTCL. She has devoted her career to improving outcomes for T-cell lymphoma patients, particularly those with PTCL-NOS, and has investigated biomarkers predictive of HDAC inhibitor response. She is a founding member of the T-Cell Lymphoma Forum and serves on multiple international PTCL guideline committees.